ESS 2012: Outcomes of Discontinuing Rivaroxaban Compared with Warfarin...

Updated:Jun 21,2012
ESS13_webheader


ESS12_Pslides_Piccini_image

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial
Presenter: Jonathan P. Piccini, Duke Clinical Research Institute, Duke University Medical Center, Durham, N.C.

Moderators: 
  • Elliott Antman
  • Robert Harrington
  • Robert Bonow
Panelists:
  • John Murkin
  • Jeffrey Weitz 
  • Mark Clay